dc.contributor.author |
Cortes, Constanza J |
|
dc.contributor.author |
La Spada, Albert R |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2018-02-01T15:06:16Z |
|
dc.date.available |
2018-02-01T15:06:16Z |
|
dc.date.issued |
2014 |
|
dc.identifier |
https://www.ncbi.nlm.nih.gov/pubmed/26942099 |
|
dc.identifier |
962402 |
|
dc.identifier.issn |
2167-5511 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/16039 |
|
dc.description.abstract |
Non-cell autonomous degeneration has arisen as an important mechanism in neurodegenerative
disorders. Using a novel line of BAC androgen receptor (AR) transgenic mice with a
floxed transgene (BAC fxAR121), we uncovered a key role for skeletal muscle in X-linked
Spinal and Bulbar Muscular Atrophy (SBMA), a motor neuronopathy caused by a polyglutamine
expansion in exon 1 of the AR gene. By excising the mutant AR transgene from muscle
only, we achieved complete rescue of neuromuscular phenotypes in these mice, despite
retaining strong CNS expression. Furthermore, we delivered an antisense oligonucleotide
(ASO) directed against the human AR transgene by peripheral injection, and documented
that peripheral ASO delivery could rescue muscle weakness and premature death in BAC
fxAR121 mice. Our results reveal a crucial role for skeletal muscle in SBMA disease
pathogenesis, and offer an appealing avenue for therapy development for SBMA and perhaps
also for related motor neuron diseases.
|
|
dc.language |
eng |
|
dc.publisher |
Informa UK Limited |
|
dc.relation.ispartof |
Rare Dis |
|
dc.relation.isversionof |
10.4161/2167549X.2014.962402 |
|
dc.subject |
Amyotrophic lateral sclerosis |
|
dc.subject |
androgen receptor |
|
dc.subject |
antisense oligonucleotide |
|
dc.subject |
motor neuron |
|
dc.subject |
neurodegeneration |
|
dc.subject |
polyglutamine |
|
dc.subject |
skeletal muscle |
|
dc.subject |
spinal and bulbar muscular atrophy |
|
dc.subject |
transgenic mice |
|
dc.title |
Motor neuron degeneration in spinal and Bulbar Muscular Atrophy is a skeletal muscle-driven
process: Relevance to therapy development and implications for related motor neuron
diseases.
|
|
dc.type |
Journal article |
|
duke.contributor.id |
Cortes, Constanza J|0810493 |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/26942099 |
|
pubs.begin-page |
e962402 |
|
pubs.issue |
1 |
|
pubs.organisational-group |
Clinical Science Departments |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Duke Institute for Brain Sciences |
|
pubs.organisational-group |
Institutes and Provost's Academic Units |
|
pubs.organisational-group |
Neurology |
|
pubs.organisational-group |
Neurology, Behavioral Neurology |
|
pubs.organisational-group |
School of Medicine |
|
pubs.organisational-group |
University Institutes and Centers |
|
pubs.publication-status |
Published online |
|
pubs.volume |
2 |
|
duke.contributor.orcid |
Cortes, Constanza J|0000-0002-6033-7428 |
|